Ticker > Company >

Sai Life Sciences share price

Sai Life Sciences Ltd.

NSE: SAILIFE BSE: 544306 SECTOR: Pharmaceuticals & Drugs  15.69 K   27   15

824.50
-20.55 (-2.43%)
BSE: 02 Sep 04:01 PM

Price Summary

Today's High

₹ 850

Today's Low

₹ 821.15

52 Week High

₹ 943

52 Week Low

₹ 635.3

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

17252.6 Cr.

Enterprise Value

16923.29 Cr.

No. of Shares

20.92 Cr.

P/E

99.46

P/B

7.77

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  106.17

CASH

457.96 Cr.

DEBT

128.64 Cr.

Promoter Holding

35.15 %

EPS (TTM)

₹  8.29

Sales Growth

15.74%

ROE

10.97 %

ROCE

15.12%

Profit Growth

82.15 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year15.74%
3 Year24.99%
5 Year17.75%

Profit Growth

1 Year82.15%
3 Year122.81%
5 Year16.7%

ROE%

1 Year10.97%
3 Year7.9%
5 Year6.68%

ROCE %

1 Year15.12%
3 Year11.44%
5 Year9.63%

Debt/Equity

0.0595

Price to Cash Flow

52.23

Interest Cover Ratio

4.2211

CFO/PAT (5 Yr. Avg.)

2.31311394038136

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 35.15 0.01
Mar 2025 35.17 2.67
Dec 2024 35.24 2.67
Sep 2024 35.24 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 122.80696420763% for the Past 3 years.
  • The company has shown a good revenue growth of 24.9851428534248% for the Past 3 years.
  • The company has significantly decreased its debt by 581.527 Cr.
  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of -99.4822 days.
  • Company has a healthy liquidity position with current ratio of 2.0179.
  • The company has a good cash flow management; CFO/PAT stands at 2.31311394038136.

 Limitations

  • Company has a poor ROE of 7.89786666666667% over the past 3 years.
  • The company is trading at a high PE of 99.46.
  • The company is trading at a high EV/EBITDA of 39.3853.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2024 Mar 2025 Jun 2025
Net Sales 428.6 567.01 483.04
Total Expenditure 317.41 413.11 370.04
Operating Profit 111.19 153.9 113
Other Income 9.45 9.82 10.01
Interest 21.66 9.16 10.7
Depreciation 31.07 34.1 34.33
Exceptional Items 0 0 0
Profit Before Tax 67.91 120.47 77.98
Tax 16.86 30.53 19.61
Profit After Tax 51.06 89.94 58.37
Adjusted EPS (Rs) 2.45 4.32 2.8

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 751.47 841.02 1157.4 1418.68 1642.05
Total Expenditure 587.29 716.14 990.53 1130.65 1249.7
Operating Profit 164.18 124.88 166.88 288.04 392.35
Other Income 27.29 28.15 27.96 29.33 37.34
Interest 32.11 50.98 74.38 81.15 71.94
Depreciation 71.77 79.7 87.77 107.21 126.03
Exceptional Items 0 0 0 0 0
Profit Before Tax 87.58 22.35 32.69 129.01 231.72
Tax 22.28 6.67 8.45 33.77 58.25
Net Profit 65.3 15.68 24.24 95.23 173.46
Adjusted EPS (Rs.) 3.67 0.89 0.98 5.39 8.32

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 17.82 17.94 18.01 18.05 20.84
Total Reserves 849.7 873.09 894.72 993.15 2146.62
Borrowings 246.44 297.17 260.97 277.25 0
Other N/C liabilities 104.61 210.12 228.29 274.89 275.67
Current liabilities 597.92 707.57 739.36 723.24 753.84
Total Liabilities 1816.49 2105.89 2141.35 2286.57 3196.97
Assets
Net Block 658.82 701.12 922.59 1073.75 1377.51
Capital WIP 192.46 188.69 151 106.9 124.46
Intangible WIP 43.62 156.47 0 0 0
Investments 63.36 63.56 80.27 80.27 114.18
Loans & Advances 63.42 49.98 34.34 73.49 59.16
Other N/C Assets 2.95 2.41 1.22 1 0.47
Current Assets 791.86 943.66 951.93 951.17 1521.19
Total Assets 1816.49 2105.89 2141.35 2286.57 3196.97
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 87.58 22.35 32.69 129.01 231.72
Adjustment 88.95 109.93 154.08 186.04 220.4
Changes in Assets & Liabilities -185.76 -35.8 38.79 -50.9 -100.28
Tax Paid -16.7 -8.11 -4.08 -13.5 -21.48
Operating Cash Flow -25.94 88.38 221.47 250.64 330.35
Investing Cash Flow -279.46 -94.63 -111.23 -190.05 -564.71
Financing Cash Flow 303.58 80.95 -190.04 -84.63 314.31
Net Cash Flow -1.81 74.7 -79.8 -24.04 79.95

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 35.24 35.24 35.17 35.15
continental wines p ltd 0.01 0.01 0.01 0.01
gokaraju subba raju 4.63 4.63 4.62 4.62
krishnam raju kanumuri - 1.45 1.44 1.44
mytreyi kanumuri 0.03 0.03 0.03 0.03
mytreyi kanumuri partner ... - 10.67 10.64 10.64
mytreyi kanumuri partner ... - 4.46 4.45 4.45
ranga raju kanumuri 0.08 0.08 0.08 0.08
ranga raju kanumuri partn... - 3.32 3.31 3.31
ranga raju kanumuri partn... - 7.50 7.48 7.48
sai quest syn private lim... 2.21 2.21 2.20 2.20
sudha kanumuri - 0.25 0.25 0.25
tanuja gokaraju - - - 0.64
tanuja gokaraju - 0.64 0.64 -
gokaraju lakshmi tanuja 0.64 - - -
kanumuri ranga raju [hol... 7.50 - - -
krishnam raju kanumuri . 1.45 - - -
mytreyi kanumuri [holding... 4.46 - - -
mytreyi kanumuri [holding... 10.67 - - -
ranga raju kanumuri [ hol... 3.32 - - -
sudha kanumuri . 0.25 - - -
PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 64.76 64.76 64.83 64.85
aditya birla sun life tru... - - - 1.57
anitha rudraraju nandyala... 1.73 1.73 1.73 1.69
axis max life insurance l... - - - 1.33
axis mutual fund trustee ... - - - 1.80
goldman sachs funds - gol... - 1.33 1.33 1.33
hbm private equity india 1.99 1.99 1.99 1.99
hsbc large & mid cap fund... - - - 1.12
inevsco india smallcap fu... - - - 4.49
nippon life india trustee... - 1.95 2.48 5.60
penmasta aruna 1.02 1.02 1.02 1.02
raju penmasta 1.11 1.11 1.11 1.11
smallcap world fund, inc - 1.35 2.62 2.62
tpg asia vii sf pte ltd 24.78 24.78 24.73 14.72
hsbc aggressive hybrid fu... - 1.25 1.12 -
invesco india midcap fund... - 2.18 2.88 -
mirae asset aggressive hy... - - 1.19 -
sivaramakrishnan chittor 1.15 - - -

Annual Reports

Title Link
Title Link
 No Annual reports exist for this company.Report us

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q3FY25

Company News

Sai Life Sciences Stock Price Analysis and Quick Research Report. Is Sai Life Sciences an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Sai Life Sciences. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Sai Life Sciences has a PE ratio of 99.5693450908959 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Sai Life Sciences has ROA of 6.3266% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Sai Life Sciences has a Current ratio of 2.0179.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Sai Life Sciences has a ROE of 10.9696%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Sai Life Sciences has a Debt to Equity ratio of 0.0595 which means that the company has low proportion of debt in its capital.

  • Sales growth: Sai Life Sciences has reported revenue growth of 15.7446% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Sai Life Sciences for the current financial year is 23.89394219901%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Sai Life Sciences is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Sai Life Sciences is Rs 8.2897. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Sai Life Sciences in Ticker for free. Also, one can get the intrinsic value of Sai Life Sciences by using Valuation Calculators, which are available with a Finology ONE subscription. 

Sai Life Sciences FAQs

Q1. What is Sai Life Sciences share price today?
Ans: The current share price of Sai Life Sciences is Rs 825.4.

Q2. What is the market capitalisation of Sai Life Sciences?
Ans: Sai Life Sciences has a market capitalisation of Rs 17271.43656168 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Sai Life Sciences?
Ans: The PE ratio of Sai Life Sciences is 99.5693450908959 and the P/B ratio of Sai Life Sciences is 7.77466104776132, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Sai Life Sciences share?
Ans: The 52-week high share price of Sai Life Sciences is Rs 943, and the 52-week low share price of Sai Life Sciences is Rs 636.1.

Q5. Does Sai Life Sciences pay dividends?
Ans: Currently, Sai Life Sciences does not pay dividends. Dividend yield of Sai Life Sciences is around 0%.

Q6. What are the face value and book value of Sai Life Sciences shares?
Ans: The face value of Sai Life Sciences shares is Rs 1, while the book value per share of Sai Life Sciences is around Rs 106.1654. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Sai Life Sciences?
Ans: Sai Life Sciences has a total debt of Rs 128.636 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Sai Life Sciences?
Ans: The ROE of Sai Life Sciences is 10.9696% and ROCE of Sai Life Sciences is 15.1166%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Sai Life Sciences a good buy for the long term?
Ans: The Sai Life Sciences long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Sai Life Sciences undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Sai Life Sciences appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Sai Life Sciences’s financials?
Ans: You can review Sai Life Sciences’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Sai Life Sciences
X